Skip to main content

Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire

Archives of Dermatological Research volume 301, pages 573–579 (2009)Cite this article

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with irreversible joint damage in a subset of individuals. There is a need to screen early for this condition to prevent damage. To meet this need, we have developed the psoriatic arthritis screening and evaluation (PASE) questionnaire. The 15-item PASE questionnaire was administered to 190 individuals with either psoriasis or PsA. The PASE questionnaire was readministered to a subset of individuals with PsA in order to assess test–retest reliability and sensitivity-to-change. Receiver operator curves were constructed to optimize sensitivity and specificity for the diagnosis of PsA. Of the 190 participating in the study, 19.5% (37/191) participants were diagnosed with PsA. PASE total scores ranged from 15 to 74 (possible range, 15–75). The PsA group had a median Total score of 51 (25th and 75th percentile 44 and 57), and non-PsA group had a median total score of 34 (25th and 75th percentile 21 and 49) (p < 0.001). A PASE total score of 44 was able to distinguish PsA from non-PsA participants with 76% sensitivity and 76% specificity. Furthermore, 13 of the 15 items demonstrated significant test–retest reliability as assessed by Pearson correlation coefficient (r ≥ 0.5). PASE was sensitive-to-change with therapy; PASE scores were significantly lower for PsA individuals after systemic therapy (p < 0.034). The PASE questionnaire is a valid and reliable tool to screen for active PsA among individuals with psoriasis. PASE scores may be used as a marker of therapeutic response.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Alenius GM (2007) Psoriatic arthritis-new insights give new options for treatment. Curr Med Chem 14(3):359–366

    PubMed  Article  CAS  Google Scholar 

  2. Alenius GM et al (2002) Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 29(12):2577–2582

    PubMed  Google Scholar 

  3. Bergman MJ (2006) Social and economic impact of inflammatory arthritis. Postgraduate Medicine Spec No: 5–11

  4. Elkayam O et al (2000) Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 19(4):301–305

    PubMed  Article  CAS  Google Scholar 

  5. Feldman SR, Fleischer AB Jr, Cooper JZ (2000) New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 39(1):41–44

    PubMed  Article  CAS  Google Scholar 

  6. Gelfand JM et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53(4):573

    PubMed  Article  Google Scholar 

  7. Gladman DD (2004) Psoriatic arthritis. Dermatol Ther 17(5):350–363

    PubMed  Article  Google Scholar 

  8. Gladman DD et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17

    PubMed  Article  Google Scholar 

  9. Gladman DD et al (2009) Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 68(4):497–501

    PubMed  Article  CAS  Google Scholar 

  10. Gorter S et al (2002) Psoriatic arthritis: performance of rheumatologists in daily practice. Ann Rheum Dis 61(3):219–224

    PubMed  Article  CAS  Google Scholar 

  11. Gottlieb AB et al (2006) Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatol Treat 17(5):279–287

    Article  Google Scholar 

  12. Huscher D et al (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65(9):1175–1183

    PubMed  Article  CAS  Google Scholar 

  13. Husni ME et al (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57(4):581–587

    PubMed  Article  Google Scholar 

  14. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42(6):778–783

    PubMed  Article  CAS  Google Scholar 

  15. Mease P, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52(1):1–19

    PubMed  Article  Google Scholar 

  16. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78

    PubMed  Article  CAS  Google Scholar 

  17. Qureshi AA et al (2008) Psoriatic arthritis screening tools. J Rheumatol 35(7):1423–1425

    PubMed  Google Scholar 

  18. Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii37–ii39 discussion ii40-1

    PubMed  Article  Google Scholar 

  19. Ruderman EM, Tambar S (2004) Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin 22(4):477–486

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

Supported by grant number T32 AR007098-34 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to the Department of Dermatology, Brigham and Women’s Hospital.

Conflict of interest statement

Dr. Qureshi is a consultant and has spoken for Abbott, Amgen, and Genentech. Dr. Husni is a consultant for Amgen, Genentech, UCB, and Roche. Dr. Husni has also been a consultant and has spoken for Centocor. Dr. Dominguez, Ms. Holt, and Ms. Tyler declare that they have no conflict of interest.

Author information

Affiliations

  1. Department of Dermatology, Center for Skin and Related Musculoskeletal Diseases, Brigham and Women’s Hospital (BWH), Harvard Medical School, 45 Francis St, 221L, Boston, MA, 02115, USA

    Patrick Lee Dominguez, Stephanie Tyler & Abrar A. Qureshi

  2. Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, USA

    M. Elaine Husni

  3. Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA

    Elizabeth W. Holt

Authors
  1. Patrick Lee Dominguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Elaine Husni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth W. Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanie Tyler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abrar A. Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Lee Dominguez.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dominguez, P.L., Husni, M.E., Holt, E.W. et al. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 301, 573–579 (2009). https://doi.org/10.1007/s00403-009-0981-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-009-0981-3

Keywords

  • Psoriasis
  • Psoriatic arthritis
  • Screening
  • Questionnaire
  • Epidemiology
  • Outcomes